The sigma-2 (σ-2) receptor: a review of recent patent applications: 2013–2018

References

• Martin WR, Eades CE, Thompson JA, et al. The effects of morphine and nalorphine-like drugs in the non-dependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976;197:517–532.
   PubMed Web of Science ®Google Scholar
• Su TP. Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to etorphine inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther. 1982;223(2):284–290.
   PubMed Web of Science ®Google Scholar
• Khazan N, Young GA, El-Fakany EE, et al. Sigma receptors mediated the psychotomimetic effects of N-allylnormetazocine (SKF-10,047), but not its opioid agonistic-antagonistic properties. Neuropharmacology. 1984;23:983–987.
   PubMed Web of Science ®Google Scholar
• Tam SW. Naloxone-inaccessible cr receptor in rat central nervous system. Proc Natl Acad Sci U S A. 1983;80: 6703–6707. Tam S. W., Cook L. Sigmaa Opiates and certain antipsychotic drugs mutually inhibit (+)-[3H]SKF10,047 and [3H]-haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci U S A, 1984; 81: 5618-5621.
   PubMed Web of Science ®Google Scholar
• Weber E, Sonders M, Quarum M, et al. 1,3-Di(2-[5-3H]tolyl)guanidine: A selective ligand that labels σ-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc Natl Acad Sci U S A. 1986;83:8784–8788.
   PubMed Web of Science ®Google Scholar
• Bowen WD, de Costa BR, Hellewell SB, et al. [3H]-(+)-Pentazocine: a potent and highly selective benzomorphan-based probe for sigma-1 receptors. Mol Neuropharmacology. 1993;3:117–126.
   PubMedGoogle Scholar
• Hanner M, Moebius FF, Flandorfer A, et al. Purification, molecular cloning, and expression of the mammalian sigma-1 binding site. Proc Natl Acad Sci U S A. 1996;93:8072–8077.
   PubMed Web of Science ®Google Scholar
• Schmidt HR, Zheng S, Guripinar E, et al. Crystal structure of the human σ1 receptor. Nature. 2016;532:527–530.
   PubMed Web of Science ®Google Scholar
• Langa F, Codony X, Tovar V, et al. Generation and phenotypic analysis of sigma receptor type I (sigma 1) knockout mice. Eur J Neurosci. 2003;18(8):2188–2196.
   PubMed Web of Science ®Google Scholar
• Xu J, Zeng C, Chu W, et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun. 2011;2(380):1–7.
   Google Scholar
• Chu UB, Mavlyutov TA, Chu ML, et al. The sigma-2 receptor and progesterone receptor membrane component 1 are different binding sites derived from independent genes. EBioMedicine. 2015;2(11):1806–1813.
   PubMed Web of Science ®Google Scholar
• Abate C, Niso M, Infantino V, et al. Elements in support of the ‘non-identity’ of the PGRMC1 protein with the σ2 receptor. Eur J Pharmacol. 2015;758:16–23.
   PubMed Web of Science ®Google Scholar
• Pati ML, Groza D, Riganti C, et al. Sigma-2 receptor and progesterone receptor membrane component 1 (PGRMC1) are two different proteins: proofs by fluorescent labeling and binding of sigma-2 receptor ligands to PGRMC1. Pharmacological Res. 2017;117:67–74.
   PubMed Web of Science ®Google Scholar
• Alon A, Schmidt HR, Wood MD, et al. Identification of the gene that codes for the σ2 receptor. Proc Natl Acad Sci. 2017;114:7160–7165.
   PubMed Web of Science ®Google Scholar
• Cognition Therapeutics (2016) Clinical trial of CT1812 in mild to moderate Alzheimer’s Disease.Clinical trial NCT02907567. [cited 2018 June 25]. Available from https://clinicaltrials.gov/ct2/show/NCT02907567?term=NCT02907567&rank=1.
   Google Scholar
• Minerva Neurosciences, Inc. Study to Evaluate Efficacy and Safety of MIN-101 in Adult Patients With Negative Symptoms of Schizophrenia, [cited 2018 June 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03397134?term=MIN-101&rank=2
   Google Scholar
• Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995;55(2):408–413.
   PubMed Web of Science ®Google Scholar
• Abramson Cancer Center of the University of Pennsylvania (2014) Imaging of in vivo sigma-2 receptor expression with ¹⁸F-ISO-1 positron emission tomography (PET/CT) in primary breast cancer. Clinical trial NCT02762110. [cited 2018 June 25]. Available from https://clinicaltrials.gov/ct2/show/NCT02762110?term=NCT02762110&rank=1
   Google Scholar
• Fan KH, Lever JR, Lever SZ. Effect of structural modification in the amine portion of substituted aminobutyl-benzamides as ligands for binding σ1 and σ2 receptors. Bioorg Med Chem. 2011;19(6): 1852–1859. Mach RH, Huang Y, Freeman RA, et al. Conformationally-flexible benzamide analogues as dopamine D3 and σ2 receptor ligands. Bioorg Med Chem Lett. 2004;14(1):195–202. Bertha CM, Mattson MV, Flippen-Anderson JL, et al. Rice KCA Marked Change of Receptor Affinity of the 2-Methyl-5-(3-hydroxyphenyl)morphans upon Attachment of an (E)-8-Benzylidene Moiety: Synthesis and Evaluation of a New Class of σ Receptor Ligands. J Med Chem. 1994; 37(19):3163–70. Bonhaus DW, Loury DN, Jakeman LB, et al. [3H]BIMU-1, a 5-hydroxytryptamine3 receptor ligand in NG-108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus. J Pharmacol Exp Ther. 1993;267(2):961–970. Zeng C, Rothfuss J, Zhang J, et al.. Sigma-2 ligands induce tumour cell death by multiple signaling pathways. Br J Cancer. 2012;106:693–701. ltzen EK., Perregaard J., Meier E., Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines. J Med Chem. 1995;38(11):2009–2017. Perregaard J, Moltzen EK, Meier E, et al. Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1.3-(Omega-aminoalkyl)-1H-indoles. J Med Chem. 1995;38(11):1998–2008. Kaushal N, Robson MJ, Vinnakota H, et al. Synthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)-benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents. AAPS J. 2011;13:336−346. Yamabe H, Okuyama M, Nakao A, et al. Preparation of cyclic amide derivatives as sigma receptor ligands, WO2001064670, 2001.
   PubMed Web of Science ®Google Scholar
• Sun YT, Wang GF, Yang YQ, et al. Synthesis and pharmacological evaluation of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives as sigma-2 receptor ligands. Eur J Med Chem. 2018;147: 227–237. Xie F, Kniess T, Neuber C, et al. Novel indole-based sigma-2 receptor ligands: synthesis, structure-affinity relationship and antiproliferative activity, Med Chem Comm. 2015;6(6):1093–1103. Wu ZW, Song SY, Li L, et al. Synthesis and evaluation of tetrahydroindazole derivatives as sigma-2 receptor ligands. Bioorg Med Chem. 2015;23(7):1463–1471. Bai S, Li S, Xu J, et al. Synthesis and Structure-Activity Relationship Studies of Conformationally Flexible Tetrahydroisoquinolinyl Triazole Carboxamide and Triazole Substituted Benzamide Analogues as σ2 Receptor Ligands, J Med Chem, 2014;57(10):4239–4251. Chu W, Xu J, Zhou D, et al. New N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs as σ2 receptor ligands: Synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents, Bioorg Med Chem. 2009;17(3):1222–1231. Vangveravong S., Xu J., Zeng C., et al. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl carbamate analogs as σ2 receptor ligands, Bioorg Med Chem. 2006;14(20):6988–6997.
   PubMed Web of Science ®Google Scholar
• Mach RH, Welch MJ, Rowland DJ, et al. Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors, US20050107398A1. 2005.
   Google Scholar
• Pryma DA, Lieberman BP, Makvandi M, et al. 211-Astatine containing radiotherapeutics for the treatment of cancer, WO2016178852A1. 2016.
   Google Scholar
• Chu UB, Mavlyutov TA, Chu ML, et al. The sigma-2 receptor and progesterone receptor membrane component 1 are different binding sites derived from independent genes. EBioMedicine. 2015;2(11): 1806–1813. Nicholson H, Mesangeau C, McCurdy CR, et al. Sigma-2 Receptors Play a Role in Cellular Metabolism: Stimulation of Glycolytic Hallmarks by CM764 in Human SK-N-SH Neuroblastoma. J Pharmacol Exp Ther. 2016;356(2):232–243. Nicholson H, Comeau A, Mesangeau C, et al. Characterization of CM572, a Selective Irreversible Partial Agonist of the Sigma-2 Receptor with Antitumor Activity. J Pharmacol Exp Ther. 2015;354(2):203–212. Robson MJ, Turner RC, Naser ZJ, et al. R. R.SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation. Exp Neurol. 2014;254:180–189. Robson MJ, Seminerio MJ, McCurdy CR, et al. Sigma receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation. Pharmacol Rep. 2013;65(2):343–349. Yous S, Wallez V, Belloir M, et al. Novel 2(3H)-benzothiazolones as highly potent and selective sigma-1 receptor ligands. Med Chem Res. 2005;14(3):158–168. Mesangeau C, Narayanan S, Green AM, et al. Conversion of a Highly Selective Sigma-1 Receptor-Ligand to Sigma-2 Receptor Preferring Ligands with Anticocaine Activity. J Med Chem. 2008;51(5):1482–1486.
   PubMed Web of Science ®Google Scholar
• Hawkins W, Mach R, Spitzer D, et al. Preparation of piperazinylmethyl quinazolinone derivatives as σ2 receptor ligand drug conjugates useful in cancer therapy, WO2015153814. 2015.
   Google Scholar
• Mccurdy CR, Mesangeau C, Chin FT, et al. Highly selective sigma receptor ligands and radioligands as probes in nociceptive processing and the pathophysiological study of memory deficits and cognitive disorders, WO2015134545. 2015.
   Google Scholar
• Charton J, Gassiot AC, Girault-Mizzi S, et al. Synthesis and pharmacological evaluation of Tic-hydantoin derivatives as selective σ1 ligands. part 1. Bioorg Med Chem Lett. 2005;15(21): 4833–4837. Gassiot AC, Charton J, Girault-Mizzi S, et al. Synthesis and pharmacological evaluation of Tic-hydantoin derivatives as selective σ1 ligands. Part 2. Bioorg Med Chem Lett. 2005;15(21):4828–4832. Toussaint M, Delair B, Foulon C, et al. Tic hydantoin sigma-1 agonist: Pharmacological characterization on cocaine-induced stimulant and appetitive effects. Eur Neuropsychopharmacology. 2009;19(7):504–515. Donnier-Marechal M, Larchanche PE, Le Broc D, et al. Carboline and phenothiazine derivatives as potent SIGMA-1 protein ligands. Eur J Med Chem, 2015;89:198–206.
   PubMedGoogle Scholar
• Melnyk P, Vermersch P, Carato P, et al. Preparation of benzamides and related derivatives useful in treating neurodegenerative diseases, WO2015193255. 2015.
   Google Scholar
• Linkens K, Schmidt HR, Sahn JJ, et al. Investigating isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties. Eur J Med Chem. 2018;151: 557–567. Mondal S, Hegarty E, Sahn JJ, et al. High-Content Microfluidic Screening Platform Used To Identify σ2R/Tmem97 Binding Ligands that Reduce Age-Dependent Neurodegeneration in C. elegans SC_APP Model, ACS Chem Neurosci. 2018;9(5):1014–1026. Sahn JJ, Mejia GL, Ray PR, et al. Sigma 2 Receptor/Tmem97 Agonists Produce Long Lasting Antineuropathic Pain Effects in Mice, ACS Chem Neurosci, 2017;8(8):1801–1811. Alon A, Schmidt HR, Wood MD, et al. Identification of the gene that codes for the σ2 receptor. Proc Natl Acad Sci USA. 2017;114(27):7160–7165. Sahn JJ, Hodges TR, Chan JZ, et al. Norbenzomorphan Scaffold: Chemical Tool for Modulating Sigma Receptor-Subtype Selectivity. ACS Med Chem Lett. 2017;8(4):455–460.
   PubMed Web of Science ®Google Scholar
• Martin SF, Sahn JJ, Hodges TR. Piperazinyl norbenzomorphane compounds and methods for using the same, WO2017070229A1. 2017.
   Google Scholar
• Rishton G, Catalano SM, Look GC. Preparation of isoindoline derivatives and their use in treating neurodegenerative diseases, WO2015116923. 2015.
   Google Scholar
• Mach RH, Zeng C, Hawkins WG. The σ2 receptor: a novel protein for the imaging and treatment of cancer. J Med Chem. 2013;56:7137−7160.
   PubMed Web of Science ®Google Scholar
• Yi B, Sahn JJ, Ardestani PM, et al. Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer’s disease. J Neurochem. 2017;140: 561−575. Izzo NJ, Xu J, Zeng C, et al. Alzheimer’s therapeutics targeting amyloid beta 1−42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS One. 2014;9:e111899.
   PubMed Web of Science ®Google Scholar
• Martin SF, Sahn JJ, Linkens KT. Sigma Receptor Binders, WO2017190109A1. 2017.
   Google Scholar
• Martin SF, Sahn JJ, Wood DM. Sigma Receptor Binders, WO2017190107A1. 2017.
   Google Scholar
• Catalano SM, Rishton G, Izzo NJ. Compositions and methods for treating neurodegenerative disease, WO2013029057. 2013.
   Google Scholar
• Guo L, Zhen X. Sigma-2 receptor ligands: neurobiological effects. Curr Med Chem. 2015;22:989–1003.
   PubMed Web of Science ®Google Scholar
• Sahn JJ, Mejia GL, Ray PR, et al. Sigma 2 receptor/Tmem97 agonists produce long lasting antineuropathic pain effects in mice. ACS Chem Neurosci. 2017;8:1801–1811.
   PubMed Web of Science ®Google Scholar
• Ebrahimi-Fakhari D, Wahlster L, Bartz F, et al. Reduction of TMEM97 increases NPC1 protein levels and restores cholesterol trafficking in Niemann-pick type C1 disease cells. Hum Mol Genet. 2016;25:3588−3599.
   PubMed Web of Science ®Google Scholar
• Bartz F, Kern L, Erz D, et al. Identification of cholesterol-regulating genes by targeted RNAi screening. Cell Metab. 2009;10(1):63–75.
   PubMed Web of Science ®Google Scholar